AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02216227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Povidone Iodine
Description: The purpose of this research is to evaluate a SSI checklist. This checklist includes decolonizing a patient's nose and skin and optimizing antibiotics prior to surgery. At the time that we wrote it, the predominate product to decolonize patient's noses was mupirocin. However, in 2017, an FDA final monograph stated that nasal povidone-iodine may be used for pre-surgical decolonization. Nasal povidone-iodine should be able to overcome barriers to checklist implementation that we identified in Aim 3. We now plan to replace the nasal agent mupirocin with the nasal agent povidone-iodine at 3 participating medical centers (Iowa City VA, Minneapolis VA and Portland VA) to assess whether this overcomes the barriers to our SSI checklist.
Study NCT01684085 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Explanation encouraging sleep
Description: An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.
Study NCT01684085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explanation discouraging sleep
Description: An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
Study NCT04133987 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLASMA-LYTE A Injection pH 7.4 (Multiple Electrolytes Injection, Type 1, USP) is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration.
Study NCT04267432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blank
Study NCT01569958 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: 1 mA stimulation for 30 seconds every 900 seconds per session
Study NCT03002012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: sertraline 400mg/day
Study NCT03002012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: matched placebo tablet
Study NCT03002012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluconazole
Description: Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).
Study NCT03002012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).
Study NCT04426331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher Without Value Information
Description: Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital. The voucher included the patient's name, the screener's name, and an expiration date 90 days from the date of screening.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. So, with this voucher, both the exam and the glasses will be completely free.
Study NCT04426331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher With Value Information
Description: Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital, which would normally cost $250. The voucher included the patient's name, the screener's name, an expiration date 90 days from the date of screening, and a statement about the $250 voucher value.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. These services normally cost about $250, but with this voucher, both the exam and the glasses will be completely free.
Study NCT05840146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Two I-strips were used:~1. The first-third of one I-strip began at the posterior iliac crest, without tension as an anchor. Then the patient actively flexed and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension.~2. The first-third of the second I-strip was applied starting at the anterior iliac crest, without tension as an anchor. The patient actively extended and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension.
Study NCT05840146 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham taping
Description: A single I-strip without tension in tape or muscle stretch. After paper backing was completely removed, tape was essentially placed on the skin across the lateral side of the hip.
Study NCT00854945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: 1800 mg/day as a 24-hour continuous intravenous infusion administered three times a week every 2 weeks
Study NCT00105703 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Case management using advanced nurse practitioners
Study NCT01923415 — intervention group
Intervention type: PROCEDURE
Intervention: No intervention, skin biopsy
Description: All participants will have 2 adjacent 4 mm punch biopsies collected from uninvolved and involved skin (a total of 4 biopsies).
Study NCT01923415 — intervention group
Intervention type: PROCEDURE
Intervention: No intervention, blood collection
Description: Blood for serum analyses will be taken from all participants, blood for DNA analysis only from subjects who consent to this separately.
Study NCT01923415 — intervention group
Intervention type: PROCEDURE
Intervention: No intervention, urine collection
Description: Urine will be collected from all participants.
Study NCT01413360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose vitamin C
Description: Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
Study NCT04045496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: JAB-3312 will be supplied as 0.25 mg and 1.0 mg capsules.
Study NCT04267432 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCI633
Description: Probiotics
Study NCT04267432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Type 2 collagen
Description: Positive control group
Study NCT00815438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystectomy.
Description: Patients enrolled in the study will have a flexible transvaginal endoscopy used during laparoscopic cholecystectomy.
Study NCT04682626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soft gelatin capsules each contains 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.
Description: Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.
Study NCT00382954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin
Study NCT00382954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: I.V., 8, or 10 or 12 mg/m\^2 weekly (days 1, 8, 15, and 22) for 4 weeks
Study NCT00457509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant
Description: 0.5 mL, Intramuscular
Study NCT00457509 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A/H5N1 inactivated, split-virion influenza vaccine
Description: 0.5 mL, Intramuscular
Study NCT03263208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).
Study NCT03263208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25-30mg/m2/day IV for 3 days(Day-5 to day-3).
Study NCT03263208 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T
Description: CD19 CAR-T cells will be administered after completion of the chemotherapy.
Study NCT02121483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin medium dose
Study NCT02121483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin high dose
Study NCT02121483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin low dose
Study NCT01768351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Zemplar cp 1 mcg/day per os
Study NCT01768351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Rocaltrol cp 0,5 mcg every other day per os
Study NCT04567875 — intervention group
Intervention type: OTHER
Intervention: No Intervention on patients
Description: No Intervention on patients
Study NCT00818428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech Production Intervention
Description: Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.
Study NCT00818428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Production Intervention
Description: Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.
Study NCT00818428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Perception Intervention
Description: Individualized intervention in which the Speech Assessment and Interactive Learning System is used to teach the child to identify recordings of words as either correct or incorrect pronunciations of the target word. In the event that the child is completely unable to pronounce the target speech sounds or word shapes focused stimulation activities are used to provide the child with further auditory exposure to the target forms. If the child stimulable for the target forms, the child is given opportunities the produce the target speech sounds or word shapes in the context of minimal pair games in which the child receives feedback about the communicative effectiveness of his or her attempts to produce the target words.
Study NCT00818428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Articulation Parent Group
Description: Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.
Study NCT01684085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam 1 mg
Study NCT00531466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolperisone HCl (AV650)
Description: One tablet orally three times a day for 28 days
Study NCT00531466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet orally three times a day for 28 days
Study NCT02220608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT02220608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study NCT01840566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Study NCT01840566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02297464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 packet of oatmeal per day
Description: 11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
Study NCT01737398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inotersen
Study NCT01737398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT00789672 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patching
Description: 2 hours daily patching
Study NCT00789672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
Study NCT04473664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Single oral dose, 30 mg tablet
Study NCT00818428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Articulation Parent Group
Description: Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.
Study NCT00818428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogic Reading Parent Group
Description: Parents are taught to read to their children using interactive techniques that help their children acquire new vocabulary, verbal reasoning abilities, and preliteracy skills.
Study NCT03472144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gel loaded with steroids (momentasone)
Description: One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local corticosteroids (momentasone) after balloon sinuplasty for chronic sinusitis patients.
Study NCT03472144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gel loaded with steroids (momentasone)
Description: One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local corticosteroids (momentasone) after balloon sinuplasty for chronic sinusitis patients.
Study NCT03472144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gel loaded with antibiotic (Levofloxacin)
Description: One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
Study NCT03472144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gel loaded with antibiotic (Levofloxacin)
Description: One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
Study NCT03472144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gel loaded with both steroids and antibiotic
Description: One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local both steroids (momentasone)and antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
Study NCT03472144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gel loaded with both steroids and antibiotic
Description: One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local both steroids (momentasone)and antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
Study NCT01068769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Taken orally, once a day in the morning for 3 weeks followed by a one week rest period
Study NCT04965662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 300 mg, TWO tablets once daily.
Study NCT04965662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Truvada one tablet once daily
Study NCT01840566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT05652452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamics
Description: Subjects in the neurodynamic group performed the 'Seated Straight Leg Slider' (SSLS) (Fig.1). To execute this sliding technique, subjects assumed a seated slump position (thoracic and lumbar flexion) which they needed to maintain throughout the exercise. This SSLS consisted of alternating movements towards knee extension and ankle dorsiflexion (increase of neural tension) combined with cervical extension (decrease of neural tension) on one hand, and knee flexion and ankle plantar flexion (decrease neural tension) combined with cervical flexion (increase of neural tension) on the other. During this 6-week period, each subject in this neurodynamic slider group was instructed to perform 3 sets of 20 repetitions on a daily basis for 6 weeks.
Study NCT05652452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static stretch
Description: Subjects in the control group were instructed to perform a standard standing static stretch with the heel of the dominant leg taking support on a chair. Then they had to move the pelvis into anteversion, simultaneously inducing a forward lean of the trunk, until the clear sensation of hamstring stretch was perceived at the posterior aspect of the thigh. Again, the execution of the exercise was thoroughly explained and evaluated by the researchers and subjects sent home with a comprehensive instruction guide and supporting pictures. Each subject was instructed to do 3 repetitions of 30 second static stretches on a daily basis during the 6-week intervention.
Study NCT01840566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT01840566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study NCT01840566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 19-28z T CELLS
Study NCT01276223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05% ophthalmic emulsion
Description: Topical ocular steroid
Study NCT01276223 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Difluprednate vehicle
Description: Inactive ingredients used as Run-In and placebo comparator
Study NCT02136147 — intervention group
Intervention type: DRUG
Intervention: methylphenidate medication
Study NCT02136147 — intervention group
Intervention type: DRUG
Intervention: atomoxetine medication
Study NCT02136147 — intervention group
Intervention type: DRUG
Intervention: lisdexamphetamine medication
Study NCT02136147 — intervention group
Intervention type: DRUG
Intervention: guanfacine medication
Study NCT01785823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FX2-2-2
Description: Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1\~3 hr and 2.0 ml/hr during 3\~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
Study NCT01858649 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metastases resection
Description: Surgery of colorectal cancer metastases will be proceeded after 3 to 6 cycles of chemotherapy ( folfox or folfiri) + bevacizumab .
Study NCT01858649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .
Study NCT01858649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FU
Description: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
Study NCT01840566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Study NCT01409642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Child CBT
Description: 12 sessions of individual child focused cognitive behavior therapy with a parent component
Study NCT01409642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Family Interaction Therapy
Description: Six sessions of family-focused treatment for childhood OCD administered as an adjunct to 12 sessions of child CBT
Study NCT01409642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Family Interaction Therapy
Description: Positive Family Interaction Therapy (PFIT) is a 6-session treatment designed to be used as an adjunct to standard child CBT in cases where OCD is complicated by challenging family dynamics.
Study NCT01932528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg [14C]-LX1606
Description: 500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as \[14C\]-LX1606.
Study NCT04030351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food - dried fruit
Description: raisins, apricots, figs, and pineapple
Study NCT04755751 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing (CPET)
Description: CPET using a cycle ergometer (COSMED, Rome, Italy) beginning with a no resistance warm up lasting 1 to 3 minutes and followed with an incrementing resistance adapted to the patient's functional capacities according to the examiner's free judgment and ranging from no resistance (20 Rounds Per Minute (RPM)/minute) 5 to 20 Watts/minute on ramps or by successive stages